<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028686</url>
  </required_header>
  <id_info>
    <org_study_id>4</org_study_id>
    <nct_id>NCT05028686</nct_id>
  </id_info>
  <brief_title>Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence</brief_title>
  <acronym>PROBE AI</acronym>
  <official_title>Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical Evaluative Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ted Rogers Centre for Heart Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peter Munk Cardiac Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vector Institute for Artificial Intelligence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical Evaluative Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective registry that aims to predict readmissions in patients with heart&#xD;
      failure, using -omics, machine learning, patient reported outcomes, clinical data and other&#xD;
      high-dimensional data sources.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is substantial need to better predict outcomes across the spectrum of heart failure&#xD;
      (HF) phenotypes in order to provide more efficient care with greater precision. Specifically,&#xD;
      no validated methods have been adopted to predict outcomes reflecting transitions in health&#xD;
      status across the continuum of HF and changes in cardiac function. A key transition is&#xD;
      hospitalization - either readmission or de novo cardiovascular hospital admission. This is a&#xD;
      major unmet health care need, to be able to better predict who will require hospital&#xD;
      admission.&#xD;
&#xD;
      Novel contributions of biomarkers, -omics, remote patient monitoring, and artificial&#xD;
      intelligence (AI). It is anticipated that prediction of readmission and many other outcomes&#xD;
      will be further improved by measurement of circulating biomarkers and by incorporating&#xD;
      methods from AI including machine learning and probabilistic generative models that can&#xD;
      incorporate the lens of how physicians and patients think. Machine learning that incorporates&#xD;
      many different types of data, including physician interpretation and a broad array of&#xD;
      biomarker/-omics molecular information can lead to significant improvements in predictive&#xD;
      accuracy. Novel multimarker strategies coupled with machine learning may enable the ability&#xD;
      of physicians to predict a range of outcomes (e.g., transitions in HF health status and LVEF)&#xD;
      and refine clinical prediction models. Furthermore, the investigators will collect patient&#xD;
      data, including patient reported outcome measures (PROMs), and physiological data (e.g. heart&#xD;
      rate, blood pressure, and daily weights data) and integrate these data points into predictive&#xD;
      models. The investigators will use the PROMs obtainable using Medly as a predictor of&#xD;
      hospitalization, and as an outcome. In this proposal, the investigators will take advantage&#xD;
      of recent advances in both deep and high throughput proteomics technologies to perform&#xD;
      high-resolution analyses. These novel factors can be integrated into new electronic&#xD;
      algorithms to improve HF care in the population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Cardiovascular readmission</measure>
    <time_frame>30 day</time_frame>
    <description>Non-elective readmission to hospital for a cardiovascular cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart failure readmission</measure>
    <time_frame>30 day</time_frame>
    <description>Non-elective readmission to hospital for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30-day</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>30-day</time_frame>
    <description>Death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause readmission</measure>
    <time_frame>30-day</time_frame>
    <description>Non-elective readmission to hospital for a any reason</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Hospitalized heart failure cohort</arm_group_label>
    <description>Patients hospitalized with heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Observational cohort</description>
    <arm_group_label>Hospitalized heart failure cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are stored in a biobank&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized heart failure patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient aged 18 years or older admitted to hospital or seen in the emergency&#xD;
             department with heart failure defined clinically&#xD;
&#xD;
          -  The diagnosis will be guided by the Framingham criteria for HF and/or BNP. A BNP &gt;400&#xD;
             will be defined as definite heart failure and BNP 100-400 classified as possible heart&#xD;
             failure.&#xD;
&#xD;
          -  Provides informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who cannot communicate due to dementia or severe cognitive deficits&#xD;
&#xD;
          -  non-Ontario residents&#xD;
&#xD;
          -  nursing home residents&#xD;
&#xD;
          -  those who are not discharged home but are discharged to a skilled nursing facility&#xD;
             (long-term care or chronic institution)&#xD;
&#xD;
          -  those who are unable to communicate who do not have a proxy (e.g. spouse or close&#xD;
             family member) to facilitate communication with the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Douglas S Lee, MD, PhD</last_name>
    <phone>4163403861</phone>
    <email>dlee@ices.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suzanne Perrett</last_name>
    <phone>4164804055</phone>
    <email>suzanne.perrett@ices.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Lee, MD, PhD</last_name>
      <phone>416-340-3861</phone>
      <email>dlee@ices.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Desana Thayaparan, BSc</last_name>
      <phone>416-340-3721</phone>
      <email>desana.thayaparan@uhn.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical Evaluative Sciences</investigator_affiliation>
    <investigator_full_name>Douglas Lee</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

